MD-logic artificial pancreas system: a pilot study in adults with type 1 diabetes.
MD-logic artificial pancreas system: a pilot study in adults with type 1 diabetes.
复制标题
DOI：
10.2337/dc09-1830
复制
发表时间：
2010-05
期刊：
影响因子：
16.2
通讯作者：
Phillip M
中科院分区：
文献类型：
--
作者：
Atlas E;Nimri R;Miller S;Grunberg EA;Phillip M
目前最先进的人工胰腺系统要么基于传统的线性控制理论，要么依赖于葡萄糖-胰岛素动力学的数学模型。由于生物系统的复杂性，使用这些方法的血糖控制是有限的。本研究的目的是描述新型MD-Logic人工胰腺（MDALG）系统的原理和临床性能。MDESTO应用模糊逻辑理论来模仿糖尿病照顾者的推理路线。它使用控制到范围和控制到目标策略的组合来自动调节个体葡萄糖水平。在7名1型糖尿病成人患者（年龄19-30岁，平均糖尿病病程10 ± 4年，平均A1 C 6.6 ± 0.7%）中进行了可行性临床研究。所有受试者均接受了14次完整的闭环对照治疗，每次8 h（空腹和进餐挑战条件）和24 h。平均餐后峰值（总疗程）葡萄糖水平为224 ± 22 mg/dl。餐后血糖水平在2.6 ± 0.6小时内恢复至<180 mg/dl，并在正常范围内保持稳定至少1小时。在24小时闭环控制期间，73%的传感器值在70和180 mg/dl之间，27%>180 mg/dl，没有一个<70 mg/dl。任何试验期间均未发生症状性低血糖事件。MDRISK系统是1型糖尿病患者个体化血糖控制的一种有前途的工具。其设计旨在最大限度地减少高血糖峰值，同时预防低血糖。计划在日常生活条件下对广大人群进行进一步研究。
Current state-of-the-art artificial pancreas systems are either based on traditional linear control theory or rely on mathematical models of glucose-insulin dynamics. Blood glucose control using these methods is limited due to the complexity of the biological system. The aim of this study was to describe the principles and clinical performance of the novel MD-Logic Artificial Pancreas (MDLAP) System. The MDLAP applies fuzzy logic theory to imitate lines of reasoning of diabetes caregivers. It uses a combination of control-to-range and control-to-target strategies to automatically regulate individual glucose levels. Feasibility clinical studies were conducted in seven adults with type 1 diabetes (aged 19–30 years, mean diabetes duration 10 ± 4 years, mean A1C 6.6 ± 0.7%). All underwent 14 full, closed-loop control sessions of 8 h (fasting and meal challenge conditions) and 24 h. The mean peak postprandial (overall sessions) glucose level was 224 ± 22 mg/dl. Postprandial glucose levels returned to <180 mg/dl within 2.6 ± 0.6 h and remained stable in the normal range for at least 1 h. During 24-h closed-loop control, 73% of the sensor values ranged between 70 and 180 mg/dl, 27% were >180 mg/dl, and none were <70 mg/dl. There were no events of symptomatic hypoglycemia during any of the trials. The MDLAP system is a promising tool for individualized glucose control in patients with type 1 diabetes. It is designed to minimize high glucose peaks while preventing hypoglycemia. Further studies are planned in the broad population under daily-life conditions.
登录
查看更多内容
影响因子：
3.2
作者：
Hovorka, R;Canonico, V;Wilinska, ME
通讯作者：
Wilinska, ME
影响因子：
5.4
作者：
Hovorka, Roman;Chassin, Ludovic J;Pieber, Thomas R
通讯作者：
Pieber, Thomas R
影响因子：
4.6
作者：
Parker, RS;Doyle, FJ;Peppas, NA
通讯作者：
Peppas, NA
影响因子：
2.2
作者：
Grant, Paul
通讯作者：
Grant, Paul
影响因子：
--
作者：
Ibbini, M. S.;Masadeh, M. A.
通讯作者：
Masadeh, M. A.